Literature DB >> 21621653

RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities.

Marina M May1, Heike Lorengel, Joerg Kreuter, Holger Zimmermann, Helga Ruebsamen-Schaeff, Andreas Urban.   

Abstract

The RNA-dependent RNA polymerase of the hepatitis C virus (HCV) is the key enzyme for viral replication, recognized as one of the promising targets for antiviral intervention. Several of the known non-nucleoside HCV polymerase inhibitors (NNIs) identified by screening approaches show limitations in the coverage of all six major HCV genotypes (GTs). Genotypic profiling therefore has to be implemented early in the screening cascade to discover new broadly active NNIs. This implies knowledge of the specific individual biochemical properties of polymerases from all GTs which is to date limited to GT 1 only. This work gives a comprehensive overview of the biochemical properties of HCV polymerases derived from all major GTs 1-6. Biochemical analysis of polymerases from 38 individual sequences revealed that the optima for monovalent cations, pH and temperature were similar between the GTs, whereas significant differences concerning concentration of the preferred cofactor Mg(2+) were identified. Implementing the optimal requirements for the polymerases from each individual GT led to significant improvements in their enzymatic activities. However, the specific activity was distributed unequally across the GTs and could be ranked in the following descending order: 1b, 6a>2a, 3a, 4a, 5a>1a. Furthermore, the optimized assay conditions for genotypic profiling were confirmed by testing the inhibitory activity of 4 known prototype NNIs addressing the NNI binding sites 1 to 4.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621653     DOI: 10.1016/j.bbapap.2011.05.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.

Authors:  Alessio Aghemo; Sherrie Bhoori; Stella De Nicola; Vincenzo Mazzaferro; Massimo Colombo
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

Review 2.  Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.

Authors:  Auda A Eltahla; Fabio Luciani; Peter A White; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2015-09-29       Impact factor: 5.048

3.  Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.

Authors:  Auda A Eltahla; Enoch Tay; Mark W Douglas; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.938

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.